Showing results (111-120 of 688) with videos related to

Sort By:
Pageof 69
Molecular Immunology|September 28, 2010
Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells to regulatory T-cell induction in non-responder mouse strainsJun Wang, Wanda G H Han, Amanda C Foks, et al.
Viral Immunology|September 22, 2006
Tumor necrosis factor-alpha genetic predisposing factors can influence clinical severity in nephropathia epidemicaPiet Maes, Jan Clement, Paul H P Groeneveld, et al.
Rheumatology (Oxford, England)|March 15, 2006
How evidence-based are advertisements in journals regarding the subspecialty of rheumatology?P van Winkelen, J S van Denderen, C Y Vossen, et al.
RMD Open|June 30, 2018
MR signal intensity: staying on the bright side in MR image interpretationJohan L Bloem, Monique Reijnierse, Tom W J Huizinga, et al.
European Journal of Immunology|July 30, 2014
IgE and IL-33-mediated triggering of human basophils inhibits TLR4-induced monocyte activationFelice Rivellese, Jolien Suurmond, Amato de Paulis, et al.
Rheumatology (Oxford, England)|September 20, 2015
Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritisWanying Li, Eric H Sasso, Annette H M van der Helm-van Mil, et al.
Seminars in Thrombosis and Hemostasis|January 16, 2024
Risk Factors for Antiphospholipid Antibodies and Antiphospholipid SyndromeRodrigo Aguirre Del-Pino, Rory C Monahan, Tom W J Huizinga, et al.
Arthritis Care & Research|January 22, 2020
Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the LiteratureNina M van Leeuwen, Jacopo Ciaffi, Jan W Schoones, et al.
The Journal of Rheumatology|June 5, 2013
Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritisAnnemarie Krabben, Rachel Knevel, Tom W J Huizinga, et al.
Arthritis Research & Therapy|March 10, 2017
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritisT W J Huizinga, A Batalov, R Stoilov, et al.
Pageof 69